{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"TSH > ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"TSH > ULN WITH TSH <= ULN AT BASELINE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"TSH > ULN WITH FT3/FT4 TEST MISSING"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"TSH < LLN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"TSH <LLN WITH TSH >= LLN AT BASELINE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"TSH < LLN WITH FT3/FT4 TEST MISSING"}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"The number of participants with laboratory abnormalities in specific thyroid tests based on SI conventional units. TSH = Thyroid Stimulating Hormone LLN = Lower Limit of Normal ULN = Upper Limit of Normal","groups":[{"description":"Four doses of nivolumab flat dose 240 mg IV were administered every 2 weeks (monotherapy phase), followed by 12 doses of the combination of AVD (adriamycin/ doxorubicin 25 mg/m2, vinblastine 6 mg/m2, dacarbazine 375 mg/m2) chemotherapy and nivolumab flat dose 240 mg IV for 6 cycles (combination phase).","id":"OG000","title":"Cohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants treated in the Cohort D combination therapy phase who had at least one on-treatment AST, ALT and/or bilirubin test measurement during the combination therapy phase","reportingStatus":"POSTED","timeFrame":"From first dose of the combination therapy to 30 days after last dose of combination therapy (an average of 8 months and a maximum of 11 months)","title":"Number of Participants Laboratory Abnormalities in Specific Thyroid Tests in Cohort D Combination Therapy Phase","type":"SECONDARY","unitOfMeasure":"Participants"}